Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells

W. Nicol Keith, Catherine M. Thomson, Jill Howcroft, Norman J. Maitland, Jerry W. Shay

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Telomerase activation is a hallmark of cancer. Advancement of telomerase as a therapeutic drug target has paved the way for translational opportunities in the related fields of senescence and cancer stem cells. Here, lessons may be learnt that can be applied to drug discovery, particularly with regard to the need to appreciate the relationships between telomerase, senescence and cancer stem cells. When considered as a time line to clinical trial, targeting of telomerase is leading the way to clinical proof-of-concept, with senescence and the cancer stem cell phenotype driving research concepts vital to maintaining a clinical development pipeline.

Original languageEnglish (US)
Pages (from-to)611-621
Number of pages11
JournalDrug Discovery Today
Volume12
Issue number15-16
DOIs
StatePublished - Aug 1 2007

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells'. Together they form a unique fingerprint.

  • Cite this